Sanofi

News

Sanofi drops two more programmes in R&D clear-out

Shortly after terminating one late-stage R&D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.

News

Sanofi gives up on amlitelimab in atopic dermatitis

Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.

News

EU seeks advice on Sanofi's response to mismarketing claim

The EU is asking for feedback on measures proposed by Sanofi to address concerns about an allegedly misleading marketing campaign for a flu vaccine.

News

Sanofi eyes extending Nexviazyme into infantile Pompe

Armed with new phase 3 data, Sanofi will try to expand the US label of its Pompe disease drug Nexviazyme to include the severe infantile-onset form.

News

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.

News

Sanofi names ex-Roche exec Fontoura as R&D chief

Paulo Fontoura, currently chief medical officer of Xaira Therapeutics, will replace Houmab Ashrafian as Sanofi's R&D head on 1st September.

Sanofi drops two more programmes in R&D clear-out

Sanofi gives up on amlitelimab in atopic dermatitis

EU seeks advice on Sanofi's response to mismarketing claim

Sanofi eyes extending Nexviazyme into infantile Pompe

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

Sanofi names ex-Roche exec Fontoura as R&D chief

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

Sanofi

Editor's Picks